Radiation

Radiotherapy Reduces Need for Anti-VEGF in Study

Oraya Therapeutics, Inc. issued positive results from the Intrepid trial. Stereotactic radiotherapy reduced the need for anti-VEGF injections by 54% for the patient sub-group characterized by the presence of significant fluid and smaller lesion size. For the full 230 patient cohort it reduced the frequency by 32%. The total procedure time is typically less than 20 minutes. Some patients will be able to go as much as one year without further treatment. The IRay system will be launched shortly in the UK.

 

Radiotherapy for AMD

Renewed interest in the efficacy of radiation therapy for neovascular AMD has prompted the initiation of large randomized clinical trials for epimacular brachytherapy.  In the past, trials for external beam techniques did not produce definitive results. This new technique provides more specific targeting of radiation to specific damaged areas with less collateral damage.  Epimacular brachytherapy has shown promising results in two pilot studies, the CABERNET trial taking place in 45 sites in the US, and the MERLOT trial in the United Kingdom.

Syndicate content